Premier Micronutrient Corporation
Stage
Acquired | AcquiredAbout Premier Micronutrient Corporation
Premier Micronutrient Corporation develops the backbone formulations in cooperation with the Department of Defense and NASA. PMC's formulations decrease oxidative damage, improve immune function, reduce inflammation, protect against neurologic symptoms and recovery from concussions, recovery from hearing and balance disorders, reversal of vascular disease and lipid abnormalities, and protection against hostile environmental factors such as radiation.
Expert Collections containing Premier Micronutrient Corporation
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Premier Micronutrient Corporation is included in 1 Expert Collection, including Vitamin & Supplement Startups.
Vitamin & Supplement Startups
662 items
Premier Micronutrient Corporation Patents
Premier Micronutrient Corporation has filed 5 patents.

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
1/11/2005 | 11/26/2013 | Glucocorticoids, Pregnanes, Transcription factors, Vitamins, Dietary supplements | Grant |
Application Date | 1/11/2005 |
---|---|
Grant Date | 11/26/2013 |
Title | |
Related Topics | Glucocorticoids, Pregnanes, Transcription factors, Vitamins, Dietary supplements |
Status | Grant |
Latest Premier Micronutrient Corporation News
Nov 9, 2018
Gladson Muthian,1 Veronica Mackey,1 Kedar Prasad,2 Clivel Charlton1 1Department of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College, Nashville, TN, USA; 2Research and Development, Antioxidant Research Institute, Premier Micronutrient Corporation, Novato, CA, USA Background: Degeneration of nigrostriatal (NS) dopamine (DA) neurons is the major neuropathological marker of Parkinson’s disease (PD). The cause for the disorder is unknown, but a prenatal sensitization stage and a postnatal precipitating stage may be involved. The sensitization stage is based on studies showing that prenatal exposure to low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) during the birth of substantia nigra (SN) DA neurons reduced DA, its metabolites, tyrosine hydroxylase (TH), the number of NS neurons as well as locomotor activities of the offspring. The observation that motor activities of the toxin-exposed animals deteriorated during aging, produced the condition equated to the precipitating stage. Other studies suggest that curcumin may offer protection. Purpose: For this project, we studied the protection offered by curcumin and an antioxidant formulation from MPTP-induced toxicity. Methods: Four groups of adult mice were pretreated, every other day for 27 days, with curcumin, 25 μg or 50 μg per mice of 25 g average body weight (equated to 1 mg/kg or 2 mg/kg) or with 25 mg/kg or 50 mg/kg of the antioxidant formulation. A control group received saline. MPTP was administer at the 20th day of pretreatment and all treatments continued for 7 days, then the animals were studied for changes in motor activities, striatal DA and DA metabolites as well as striatal and midbrain TH. The changes are indicative of PD-like NS damage. Results: The data showed that MPTP markedly reduced movements, as well as DA, its metabolites and TH. Curcumin and the antioxidant formulation blocked and ameliorated the toxic effects of MPTP. MPTP reduced DA to 49.1%. Curcumin restored DA to 87.3% and 84.8%, and the antioxidants restored and elevated DA to 132.1% and 121.2%. MPTP reduced striatal TH to 45.1%. The doses of curcumin restored TH to 60.9% and 75.1% and the antioxidants restored TH to 90.7% and 94.7%. Curcumin and the antioxidants reduced MPTP-induced death. Conclusion: The results demonstrated that curcumin and the antioxidants blocked the PD-like toxic effects of MPTP, indicative of the potentials as preventative measure for PD. Keywords: antioxidants, curcumin, dopamine, tyrosine hydroxylase, Parkinson’s disease This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License . By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms .
Premier Micronutrient Corporation Frequently Asked Questions (FAQ)
Where is Premier Micronutrient Corporation's headquarters?
Premier Micronutrient Corporation's headquarters is located at Greenwood Village.
What is Premier Micronutrient Corporation's latest funding round?
Premier Micronutrient Corporation's latest funding round is Acquired.
Who are the investors of Premier Micronutrient Corporation?
Investors of Premier Micronutrient Corporation include NewAge.